Status:
WITHDRAWN
Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia
Lead Sponsor:
Cellectis S.A.
Conditions:
Acute Myeloid Leukaemia
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This is a Phase I, open-label, dose escalation study of UCART123 administered intravenously to patients with newly diagnosed CD123 positive adverse genetic risk acute myeloid leukaemia (AML) defined i...
Eligibility Criteria
Inclusion
- Main Inclusion Criteria:
- Patients newly diagnosed with CD123 positive adverse genetic risk acute myeloid leukaemia (AML) defined as per ELN guidelines (Döhner et al., 2017)
- Eastern Cooperative Oncology Group performance status of 0 or 1
- No prior gene or experimental cellular therapy
- No organ dysfunction that in the opinion of the investigator precludes intensive induction chemotherapy or cellular therapy
Exclusion
Key Trial Info
Start Date :
July 11 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 5 2019
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04106076
Start Date
July 11 2019
End Date
December 5 2019
Last Update
July 14 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.